129 related articles for article (PubMed ID: 2412489)
1. Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs.
Ikeda S; Negishi T; Nishimura C
Antiviral Res; 1985 Aug; 5(4):207-15. PubMed ID: 2412489
[TBL] [Abstract][Full Text] [Related]
2. Enhancement by muramyldipeptides of the activities of early-type inducers of interferon.
Ikeda S; Matsuda Y; Nishimura C
Antiviral Res; 1985 Dec; 5(6):345-53. PubMed ID: 2418780
[TBL] [Abstract][Full Text] [Related]
3. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
[TBL] [Abstract][Full Text] [Related]
5. Effect of N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl- L-lysine on resistance to herpes simplex virus type-1 infection in cyclophosphamide-treated mice.
Ishihara C; Iida J; Mizukoshi N; Yamamoto N; Yamamoto K; Kato K; Azuma I
Vaccine; 1989 Aug; 7(4):309-13. PubMed ID: 2554602
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative.
Ikeda S; Yazawa M; Nishimura C
Antiviral Res; 1987 Oct; 8(3):103-13. PubMed ID: 2827566
[TBL] [Abstract][Full Text] [Related]
7. [Herpes simplex virus and macrophages].
Scieux C
Pathol Biol (Paris); 1997 Feb; 45(2):159-64. PubMed ID: 9247038
[TBL] [Abstract][Full Text] [Related]
8. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
9. Immunostimulatory activity of 1-O-acylated muramyl dipeptides, with or without a 6-O-phosphoryl group, in aqueous form.
Furuya T; Kumazawa Y; Takimoto H; Nagumo T; Nagamine T; Aizawa C; Mizunoe K; Kiso M; Hasegawa A; Nomoto K
Int J Immunopharmacol; 1989; 11(1):35-43. PubMed ID: 2496044
[TBL] [Abstract][Full Text] [Related]
10. Experimental and clinical studies on the effects of synthetic muramyldipeptide derivatives on viral and opportunistic infections.
Yamamura Y; Ishihara C; Hamada N; Yamamoto K; Azuma I
Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):11-4. PubMed ID: 3010013
[TBL] [Abstract][Full Text] [Related]
11. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of host-defense mechanism with synthetic adjuvants and recombinant cytokines against viral infection in mice.
Azuma I; Ishihara C; Iida J; Yoo YC; Yoshimatsu K; Arikawa J
Adv Exp Med Biol; 1992; 319():253-63. PubMed ID: 1329443
[TBL] [Abstract][Full Text] [Related]
13. Effect of N-acetyl-muramyl-L-alanyl-D-isoglutamine on interferon production in mice by Newcastle disease virus.
Sakuma T; Azuma M; Yoshida I
J Gen Virol; 1984 May; 65 ( Pt 5)():999-1003. PubMed ID: 6202835
[TBL] [Abstract][Full Text] [Related]
14. Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
Ishihara C; Mizukoshi N; Iida J; Kato K; Yamamoto K; Azuma I
Vaccine; 1987 Dec; 5(4):295-301. PubMed ID: 2448969
[TBL] [Abstract][Full Text] [Related]
15. IL-23 enhances host defense against vaccinia virus infection via a mechanism partly involving IL-17.
Kohyama S; Ohno S; Isoda A; Moriya O; Belladonna ML; Hayashi H; Iwakura Y; Yoshimoto T; Akatsuka T; Matsui M
J Immunol; 2007 Sep; 179(6):3917-25. PubMed ID: 17785829
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs.
Dietrich FM; Hochkeppel HK; Lukas B
Int J Immunopharmacol; 1986; 8(8):931-42. PubMed ID: 2433236
[TBL] [Abstract][Full Text] [Related]
17. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
[TBL] [Abstract][Full Text] [Related]
18. Macrophage extrinsic antiviral activity during herpes simplex virus infection.
Morahan PS; Morse SS; McGeorge MG
J Gen Virol; 1980 Feb; 46(2):291-300. PubMed ID: 6247426
[TBL] [Abstract][Full Text] [Related]
19. An M2 Rather than a T
Lee DH; Ghiasi H
J Virol; 2018 May; 92(10):. PubMed ID: 29491152
[TBL] [Abstract][Full Text] [Related]
20. The role of natural killer cells and interferon in resistance to acute infection of mice with herpes simplex virus type 1.
Bukowski JF; Welsh RM
J Immunol; 1986 May; 136(9):3481-5. PubMed ID: 2420892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
